Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant

Queen's University (Kingston, Ontario)

$706,058.00

Roles of F-BAR proteins in lung cancer progression and metastases

EF 2011-12

Résumé
Lung cancer is one of the most frequent types of cancer, but is by far the most deadly with a 5-year survival rate of 14%. Clearly, there is a real need for improvements in early diagnosis, and development of new therapeutic approaches. Considering that the most frequent cause of lung cancer-related death is due to the spread of lung tumours to other organs, new therapeutics designed to halt the spread of cancer cells could save lives. Our goal is to uncover key proteins involved in the spread of cancer, and thereby identify new therapeutic targets in lung cancer.
Programme
Operating Grant
Emplacement
Ontario, Canada
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
238634
Name
Craig Andrew W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Roles of F-BAR proteins in lung cancer progression and metastases
Programtype2
Operating Grants
Orgnameinp2
Queen's University (Kingston, Ontario)
Cihramount2
$706,058
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Cell Invasion; Cell Migration; Endocytosis; Epidermal Growth Factor Receptor; F-Bar Proteins; Lung Cancer; Metastases; Tumour Xenograft
Abstract
Lung cancer is one of the most frequent types of cancer, but is by far the most deadly with a 5-year survival rate of 14%. Clearly, there is a real need for improvements in early diagnosis, and development of new therapeutic approaches. Considering that the most frequent cause of lung cancer-related death is due to the spread of lung tumours to other organs, new therapeutics designed to halt the spread of cancer cells could save lives. Our goal is to uncover key proteins involved in the spread of cancer, and thereby identify new therapeutic targets in lung cancer.
Competitiondate
201109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Craig, Andrew W
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $706,058~ $0~